249 related articles for article (PubMed ID: 24958351)
21. Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.
Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Del Barco S; Martin-Castillo B; Menendez JA
J Cell Physiol; 2011 Jan; 226(1):52-7. PubMed ID: 20658522
[TBL] [Abstract][Full Text] [Related]
22. Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors.
Yeh ES; Abt MA; Hill EG
Breast Cancer Res Treat; 2015 Jan; 149(1):91-8. PubMed ID: 25515931
[TBL] [Abstract][Full Text] [Related]
23. Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells.
Chang Y; Park KH; Lee JE; Han KC
Biochem Biophys Res Commun; 2018 Oct; 505(1):187-193. PubMed ID: 30243723
[TBL] [Abstract][Full Text] [Related]
24. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
[TBL] [Abstract][Full Text] [Related]
25. The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.
Dragowska WH; Weppler SA; Qadir MA; Wong LY; Franssen Y; Baker JH; Kapanen AI; Kierkels GJ; Masin D; Minchinton AI; Gelmon KA; Bally MB
BMC Cancer; 2011 Oct; 11():420. PubMed ID: 21961653
[TBL] [Abstract][Full Text] [Related]
26. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
[TBL] [Abstract][Full Text] [Related]
27. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.
Borrero-García LD; Del Mar Maldonado M; Medina-Velázquez J; Troche-Torres AL; Velazquez L; Grafals-Ruiz N; Dharmawardhane S
BMC Cancer; 2021 Jun; 21(1):652. PubMed ID: 34074257
[TBL] [Abstract][Full Text] [Related]
28. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
29. PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.
Moody SE; Schinzel AC; Singh S; Izzo F; Strickland MR; Luo L; Thomas SR; Boehm JS; Kim SY; Wang ZC; Hahn WC
Oncogene; 2015 Apr; 34(16):2061-71. PubMed ID: 24909179
[TBL] [Abstract][Full Text] [Related]
30. A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
O'Shea J; Cremona M; Morgan C; Milewska M; Holmes F; Espina V; Liotta L; O'Shaughnessy J; Toomey S; Madden SF; Carr A; Elster N; Hennessy BT; Eustace AJ
Oncotarget; 2017 Oct; 8(49):85120-85135. PubMed ID: 29156708
[TBL] [Abstract][Full Text] [Related]
31. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
Garrett JT; Sutton CR; Kuba MG; Cook RS; Arteaga CL
Clin Cancer Res; 2013 Feb; 19(3):610-9. PubMed ID: 23224399
[TBL] [Abstract][Full Text] [Related]
32. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
Collins DM; Gately K; Hughes C; Edwards C; Davies A; Madden SF; O'Byrne KJ; O'Donovan N; Crown J
Cell Immunol; 2017 Sep; 319():35-42. PubMed ID: 28735814
[TBL] [Abstract][Full Text] [Related]
33. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
[TBL] [Abstract][Full Text] [Related]
34. Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.
Sethunath V; Hu H; De Angelis C; Veeraraghavan J; Qin L; Wang N; Simon LM; Wang T; Fu X; Nardone A; Pereira R; Nanda S; Griffith OL; Tsimelzon A; Shaw C; Chamness GC; Reis-Filho JS; Weigelt B; Heiser LM; Hilsenbeck SG; Huang S; Rimawi MF; Gray JW; Osborne CK; Schiff R
Mol Cancer Res; 2019 Nov; 17(11):2318-2330. PubMed ID: 31420371
[TBL] [Abstract][Full Text] [Related]
35. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.
Jin Q; Yuan LX; Boulbes D; Baek JM; Wang YN; Gomez-Cabello D; Hawke DH; Yeung SC; Lee MH; Hortobagyi GN; Hung MC; Esteva FJ
Breast Cancer Res; 2010; 12(6):R96. PubMed ID: 21080941
[TBL] [Abstract][Full Text] [Related]
36. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.
Liu L; Greger J; Shi H; Liu Y; Greshock J; Annan R; Halsey W; Sathe GM; Martin AM; Gilmer TM
Cancer Res; 2009 Sep; 69(17):6871-8. PubMed ID: 19671800
[TBL] [Abstract][Full Text] [Related]
37. Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Collins DM; Madden SF; Gaynor N; AlSultan D; Le Gal M; Eustace AJ; Gately KA; Hughes C; Davies AM; Mahgoub T; Ballot J; Toomey S; O'Connor DP; Gallagher WM; Holmes FA; Espina V; Liotta L; Hennessy BT; O'Byrne KJ; Hasmann M; Bossenmaier B; O'Donovan N; Crown J
Clin Cancer Res; 2021 Feb; 27(3):807-818. PubMed ID: 33122343
[TBL] [Abstract][Full Text] [Related]
38. Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells.
Ma C; Zuo W; Wang X; Wei L; Guo Q; Song X
Oncol Rep; 2013 Feb; 29(2):812-8. PubMed ID: 23229346
[TBL] [Abstract][Full Text] [Related]
39. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
[TBL] [Abstract][Full Text] [Related]
40. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
O'Brien NA; Browne BC; Chow L; Wang Y; Ginther C; Arboleda J; Duffy MJ; Crown J; O'Donovan N; Slamon DJ
Mol Cancer Ther; 2010 Jun; 9(6):1489-502. PubMed ID: 20501798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]